Cytokinics stock surges after heart drug trial success
Cytokinetics' stock hit a 52-week high following the ACACIA-HCM Phase 3 trial results, which met both primary endpoints. The trial evaluated aficamten for obstructive hypertrophic cardiomyopathy, potentially expanding treatment to a broader patient population. The positive data drove investor confidence, pushing shares upward. The company plans to seek regulatory approval.
Key facts
- Cytokinetics stock reached a 52-week high
- ACACIA-HCM Phase 3 trial met both primary endpoints
- Drug aficamten targets obstructive hypertrophic cardiomyopathy
- Trial results could expand treatment to new patient population
- Positive data boosted investor confidence
- Company plans regulatory submission
Entities
Institutions
- Cytokinetics
Sources
- Quartz —